Double immunotherapy combo aims to boost lung cancer surgery outcomes

NCT ID NCT05825625

Ongoing Disease control Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase II trial investigates whether adding two immunotherapy drugs—tiragolumab and atezolizumab—to standard chemotherapy before and after surgery can improve outcomes for people with resectable non-small cell lung cancer. The study enrolls 35 adults with stage II to IIIB disease. The main goal is to see how many patients have a major pathological response (fewer than 10% viable tumor cells remaining) after treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: tiragolumab and atezolizumab (immunotherapy drugs) plus chemotherapy
What this could lead to: If successful, this combination could become a new standard treatment before and after lung cancer surgery, potentially improving cure rates.
What could go wrong: This is a small, early-phase study with only 35 participants, so results may not apply to all patients. Immunotherapy combinations can cause serious side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

Thoraxklinik Heidelberg

Heidelberg, 69126, Germany
Universitätsklinikum Essen (AöR)-Westdeutsches Tumorzentrum Essen

Essen, 45147, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.